Translate Bio to Participate in Upcoming Investor Conferences
November 12, 2020 07:30 ET
|
Translate Bio, Inc.
LEXINGTON, Mass., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...
Translate Bio Announces Third Quarter 2020 Financial Results and Reviews Recent Progress
November 05, 2020 16:21 ET
|
Translate Bio, Inc.
-- Advances Phase 1/2 clinical trial of MRT5005 for the treatment of cystic fibrosis (CF) with resumption of COVID-impacted enrollment and dosing -- -- Presented promising preclinical data at NACFC...
Sanofi and Translate Bio mRNA COVID-19 Vaccine Candidate Induced High Antibody Levels in Preclinical Studies
October 15, 2020 08:00 ET
|
Translate Bio, Inc.
-- mRNA-based vaccine candidate MRT5500 induced potent neutralizing antibodies against SARS-CoV-2 in preclinical studies -- -- Two doses of MRT5500 induced neutralizing antibody levels significantly...
Translate Bio Highlights mRNA Platform Potential for the Treatment of Cystic Fibrosis (CF) at the 34th Annual North American Cystic Fibrosis Conference
October 07, 2020 16:05 ET
|
Translate Bio, Inc.
-- Lead candidate MRT5005 leverages Translate Bio’s proprietary LNP and mRNA platform and is the only clinical-stage mRNA therapeutic in development for the treatment of CF -- -- Second CF program,...
Translate Bio to Participate in Upcoming Investor Conferences
September 29, 2020 16:05 ET
|
Translate Bio, Inc.
LEXINGTON, Mass., Sept. 29, 2020 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...
Translate Bio Resumes Enrollment and Dosing in Phase 1/2 Clinical Trial of MRT5005 in Cystic Fibrosis
September 08, 2020 07:30 ET
|
Translate Bio, Inc.
LEXINGTON, Mass., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...
Translate Bio to Participate in Upcoming Investor Conferences
September 03, 2020 07:30 ET
|
Translate Bio, Inc.
LEXINGTON, Mass., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...
Translate Bio Announces Closing of Expanded Collaboration and Licensing Agreement with Sanofi Pasteur to Develop mRNA Vaccines for All Infectious Diseases
July 20, 2020 16:05 ET
|
Translate Bio, Inc.
LEXINGTON, Mass., July 20, 2020 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...
Translate Bio Announces Proposed Public Offering of Common Stock
June 24, 2020 16:18 ET
|
Translate Bio, Inc.
LEXINGTON, Mass., June 24, 2020 (GLOBE NEWSWIRE) -- Translate Bio, Inc. (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially...
Sanofi and Translate Bio Expand Collaboration to Develop mRNA Vaccines Across All Infectious Disease Areas
June 23, 2020 00:59 ET
|
Translate Bio, Inc.
-- The two companies will build upon their existing collaboration to pursue novel mRNA vaccines aimed at broadly addressing current and future infectious diseases -- -- Translate Bio to receive...